 SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Equity Index Series GEIS, following FTSEs most recent semi-annual review. 